AstraZeneca Develops Breakthrough Acoustic Dispensing with Mass Spectrometry for Ultra High-Throughput Screening

3 February 2016

Hear how combining acoustic liquid handling and mass spectrometry can produce high quality data, increase throughput and reduce both assay development and screening costs by 100- to 1000-fold, in the pharmaceutical industry. AstraZeneca, together with Labcyte, have developed a new solution to optimize drug discovery screening and encourage collaborations between academic researchers and industrial partners.  AstraZeneca’s Vice-President of Screening Sciences and Sample Management, Steve Rees, and Principal Scientist, Jonathan Wingfield, discuss the impact of acoustic dispensing with mass spectrometry in the area of metabolomics, low level analytes, and drug discovery screening.